Search results
Results from the WOW.Com Content Network
Guidelines on the choice of agents and how best to step up treatment for various subgroups in hypertension (high blood pressure) have changed over time and differ between countries. A Comparison of International Guidelines on Goal Blood Pressure and Initial Therapy for Adults With Hypertension (adapted from JNC 8 guidelines [ 1 ] )
For most people, recommendations are to reduce blood pressure to less than or equal to somewhere between 140/90 mmHg and 160/100 mmHg. [2] In general, for people with elevated blood pressure, attempting to achieve lower levels of blood pressure than the recommended 140/90 mmHg will create more harm than benefits, [3] in particular for older people. [4]
Blood pressure targets [7] <1 hr 25% reduction in the mean arterial pressure, diastolic blood pressure above 100 2-6 hr Systolic BP < 160 mmHg or Diastolic BP <110 mmHg 6-24 hr monitor BP targets, ensure non-rapid drop in BPs below 160 SBP or 100 DBP 1-2 d if no end-organ damage, monitor out-patient and JNC8 Guidelines for maintaining BP control
Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke, heart failure, kidney failure and myocardial infarction. Evidence suggests that a reduction of blood pressure by 5 mmHg can decrease the risk of stroke by 34% and of ischaemic heart disease by 21%.
Hypertension, also known as high blood pressure, is a long-term medical condition in which the blood pressure in the arteries is persistently elevated. [11] High blood pressure usually does not cause symptoms itself. [ 1 ]
Hypertension or high blood pressure affects at least 26.4% of the world's population. [15] Hypertensive heart disease is only one of several diseases attributable to high blood pressure. Other diseases caused by high blood pressure include ischemic heart disease, cancer, stroke, peripheral arterial disease, aneurysms and kidney disease.
Prehypertension, also known as high normal blood pressure and borderline hypertensive (BH), [1] is a medical classification for cases where a person's blood pressure is elevated above optimal or normal, but not to the level considered hypertension (high blood pressure).
The National Heart, Lung, and Blood Institute (NHLBI) is the third largest Institute of the National Institutes of Health, located in Bethesda, Maryland, United States.It is tasked with allocating about $3.6 billion in FY 2020 [1] in tax revenue to advancing the understanding of the following issues: development and progression of disease, diagnosis of disease, treatment of disease, disease ...